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Background: When depressed patients are in remission, the clinical characteristics indicate that they are able to
participate in social activities more regularly, and their impairment in daily functioning is improved. The present
study examines the clinical characteristics associated with one- and two month clinical response in outpatients with
Major Depressive Disorder (MDD) in Taiwan.
Methods: A total of 160 outpatients were initially recruited from the medical centre in Taiwan. Of these
participants, 151 MDD patients completed the baseline-assessment interview, 111 were interviewed and assessed
again 4 weeks later, and 78 completed the final interview and assessment 8 weeks later. In the present study,
asymptomatic was defined as scoring ≤ 7 on the Hamilton Depression Rating Scale (HAM-D); partially symptomatic
was defined as scoring 8–14; fully symptomatic was defined as scoring ≥15. Finally, asymptomatic, partially symptomatic,
and fully symptomatic were defined in patients with MDD respectively as in full remission, in persistent depressive
symptom, and in episode.
Results: Of the remaining 78 patients, a total of 21 (26.9%) were in full remission, 35 (44.9%) were in persistent
depressive symptom, and 22 (28.2%) were in episode. Patients in full remission were older (p = 0.03), exhibited greater
psychosocial functioning, (p < 0.001), held more-positive beliefs regarding antidepressant medication (p = 0.03), had
higher self-efficacy (p = 0.001), and scored lower for neuroticism (p = 0.003), as compared to patients in episode.
Younger patients were more prevalent in persistent depression. Repeated-measures ANOVA revealed that differences in
four factors (psychosocial functioning, beliefs regarding antidepressant medication, self-efficacy in managing and
preventing depression, and neuroticism) were significantly different between full remission and episode. Episode was
significantly associated with psychosocial-functioning impairment (OR = 1.12, 95% CI: 1.00-1.26) and poorer self-efficacy
(OR = 0.91, 95% CI: 0.82-1.00).
Conclusions: Our findings identify significant factors of full remission, persistent depressive symptom, and episode. We
highlight the importance of enhancing patients’ psychosocial functioning and self-efficacy until achieving full remission.
Suggestions are provided for clinical health-care management services in Taiwan.
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Depression is a severe illness. It is a recurring, disabling
condition with high costs, such as extensive pharmaco-
therapy and decreased personal productivity, profoundly
affecting patients’ lives [1]. A recent study shows a low
remission rate for Major Depressive Disorder (MDD) pa-
tients after taking antidepressant medication for 3 to
12 months in primary care practice: 28.3% according to
the general practitioners and 17.1% according to the pa-
tients [2]. Another study showed that approximately two
thirds of patients failed to achieve full remission, and
only 26% reached full remission after 6 months with
acute antidepressant-medication treatment [3].
Remission, featuring a Hamilton Depression Rating
Scale (HAM-D) score of seven or less, means that a pa-
tient has been in a symptom-free state and has returned
to normal levels of psychosocial functioning [4-6]. Treat-
ing depressed patients until they reach a state of remis-
sion confers the benefit of reduced risk of relapse or
recurrence [2,7]. The consequences of achieving full
symptom resolution could be greater psychosocial func-
tioning and quality of life for the patients with major de-
pression [2,8]. The social- and occupational functioning
and quality of life for patients diagnosed with depression
appear to be negatively influenced by their illness [3,4].
However, when depressed patients are in remission, the
clinical characteristics indicate that they are able to par-
ticipate in social activities more regularly, and their im-
pairment in daily functioning is improved. In addition,
they are more confident in managing their depression
and preventing a relapse of depression; are more likely
to express positive beliefs regarding antidepressant medi-
cation; and reveal a lower level of neurosis [4,9]. Self-
efficacy is a significant characteristic of remission in
regards to controlling or preventing future episodes
[10,11]. Promoting self-efficacy for managing depression
(e.g. regular keeping track of depressive symptoms using
a depression symptom inventory, engaging in pleasant
activities and engaging in social activities) increased the
likelihood of performing several behaviors related to
controlling depression [11].
Katon et al. [12] found that relapse-prevention pro-
grams were strongly associated with improvement of be-
liefs regarding antidepressant medication, as well as a
significant decrease in depression symptoms. A lower
adherence to antidepressant medication is consistently
associated with a higher rate of relapse [11,13]. If the pa-
tient remains asymptomatic while taking medication, she
will have more-positive beliefs regarding medication
[12]. Neuroticism is a broad, higher-order personality
factor that refers to emotional instability and vulnerabil-
ity to stress [14]. Accordingly, it might be expected that
levels of neuroticism could be used to predict depres-
sion, either as a main effect or stemming from stressfullife events (such as financial failures, failure to resolve
interpersonal conflicts or problems, etc.) [14].
The research results of Romera et al. [3] clearly
emphasize the importance of treating the patient until
achieving full remission as opposed to partial remission,
because the “persistence of partial remission has been
associated with an increased risk of relapse, poorer qual-
ity of life, and disability”. Full remission is defined as the
individual being asymptomatic for 2 weeks to 6 months,
a symptom-free state with a return to pre-morbid func-
tioning, i.e. normal levels of psychosocial functioning
[9]. Ciudad [15] reported that in the clinical course of
major depression, early response within 6 weeks and re-
mission was strongly associated with good outcomes at a
12-month follow-up. Kocsis [16] indicated remission as
the greatest predictor of continued remission during
2 years of follow-up. Therefore, the question arises as to
how to facilitate remission or recovery from depression.
The objective of this study was to use the HAM-D to
examine clinical factors associated with full remission
and episodes of MDD.
Methods
Participants
All participants were selected and interviewed by their
psychiatrist in the outpatient-services clinic in the de-
partment of psychiatry of a medical centre in southern
Taiwan. Participants were diagnosed with MDD by 11 psy-
chiatrists using the DSM-IV criteria, but those with per-
sonality disorders, bipolar disorder, substance-induced
depression, and psychosis with depression were excluded.
A total of 160 outpatients were initially recruited from
the medical centre in Taiwan. Of these participants, 151
completed the baseline interview, 111 subjects com-
pleted the second interview after 4 weeks, and 78 outpa-
tients completed the third interview after 8 weeks. The
recruitment procedure is shown in Figure 1.
Ethical considerations
The recruitment protocol and the study protocol were ap-
proved by the institutional review boards of the Kaohsiung
Chang Gung Memorial Hospital in Taiwan. Before con-
tacting participants, researchers communicated and ex-
plained the research procedure and recruiting criteria to
psychiatrists, and emphasised that subjects’ responses
would be anonymous and confidential, unless subjects
agreed to share the results with their physicians.
Measures
Hamilton depression rating scale (HAM-D)
Since the HAM-D was published in 1960, it has been used
as an instrument for assessing the severity of depression
and response to therapy in clinical research. It is the most
popular measure to evaluate remission [6,17]. Keller [4]
Figure 1 The recruitment procedure of outpatients with MDD.
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atic, and an asymptomatic state continuing for two weeks
to six months was defined as reaching a state of remission.
Fully symptomatic was defined as scoring ≥15. Being in
episode was defined as remaining fully symptomatic for
more than two weeks.
In the present study, the HAM-D evaluations were
available for baseline interviews, the second interview
after 4 weeks, and the third interview after 8 weeks. Pa-
tients who were asymptomatic at the baseline interview
we’re not included in this study. Being in full remission
was defined as scoring ≤7 at both 4 weeks and 8 weeks.
Being in episode was defined as remaining fully symp-
tomatic at both 4 weeks and 8 weeks. Being in persistentTable 1 Operational definition of full remission and persisten
Hamilton rating scale in this study
Definition Baselin





Partially or fully symptomatic
at ≥4 weeks
Score >
Episode Fully symptomatic at ≥4 weeks Score >depressive symptom was defined as being neither in full
remission (scoring ≤7 at 4 weeks and 8 weeks), nor in
episode (scoring ≥15 at 4 weeks and 8 weeks), but at
least once partially or fully symptomatic (Table 1).Psychosocial functioning
The three psychosocial-functioning factors with regard
to health’s impact level in daily life, adapted from the
National Health Interview Survey [10], are: occupational
function, daily life with family, and leisure and social ac-
tivities. Each psychosocial functioning factor is scored
from 0 to 10, with higher scores representing greater im-
pairment of psychosocial functioning.t depression
e After 4 weeks After 8 weeks
7 Asymptomatic (Score ≤ 7) Asymptomatic (Score ≤ 7)
7 At least once partially (Score 8–14) or fully symptomatic (Score ≥15)
7 Fully symptomatic (Score ≥15) Fully Symptomatic (Score ≥15)
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The 12-item Medication Beliefs Scale, in a 5-point Likert
format, is a reliable and valid instrument to measure be-
liefs about medication, with responses ranging from 1
(Strongly Disagree) to 5 (Strongly Agree). Items include,
for example: “drugs for anxiety or depression are not the
answer to problems in one’s life”; “prescription drugs are
a crutch”; and “I should be able to get by without using
these kinds of drugs”. The 12 items are scored to pro-
vide a measure of overall confidence in antidepressant
medication ranging from 0 to 5, with higher scores
representing greater confidence in antidepressant medi-
cation. The original-scale Cronbach’s alpha for this 12-
item score was 0.81, following which all 12 items were
loaded into one factor in the Principle Component
Analysis [12].
Self-efficacy for managing depression
Self-efficacy was assessed using a 6-item scale which
consisted of 2 global questions on managing and pre-
venting depression, and 4 items for specific behavioral
issues [11]. Items included: 1) How confident are you in
your ability to overcome or control a bout of depression?
2) How confident are you in your ability to prevent de-
pression from returning once you are better? 3) How
confident are you in your ability to recognize early on
when you are starting to get depressed? The 6 items are
scored from 0 to 10, providing a measure of overall self-
efficacy, with higher scores representing greater confi-
dence of self-efficacy for managing depression.
Personality traits
The 60-item NEO Personality Inventory isolates five gen-
eral personality traits: neuroticism, extroversion, openness
to experience, agreeableness, and conscientiousness [18].
The 60 items, with Likert-scale responses ranging from 1
(Strongly Disagree) to 5 (Strongly Agree), are scored to
provide a measure of the traits, with higher scores repre-
senting higher neuroticism.
Procedures
All processes involving patients were coordinated with
an outpatient-treatment clinic. The research instruments
were back-translated into Chinese by the researchers,
and pre-tested with twenty depressed patients. All par-
ticipants were referred by their psychiatrist. The re-
searchers explained to each participant that the main
purpose of the study was to identify treatment strategies
for primary care settings. It was emphasized that all pro-
cesses were anonymous and voluntary; the risks and
benefits of participation were explained, including pa-
tients’ right to refuse to participate without jeopardising
treatment. Subsequent to this explanation, patients who
decided to participate in the interviews signed aninformed-consent form. All patients were treated by psy-
chiatrists and were provided with pharmacotherapy and
clinical management, including discussing the effects
and side-effects of medication, encouraging the patient
to comply with the medication regimen, and provid-
ing practical and emotional support. Following this,
data was collected through one-on-one interviews
with the researchers and self-reporting of participants
on questionnaires.
In this study, in order to reduce participant dropout,
the researcher visited each patient at the psychiatric
clinic, and reconfirmed participation by telephone before
the follow-up interviews at 4 weeks and 8 weeks. Also,
the participants received NT$200 dollars after each of
their interviews were completed.
Statistics analysis
Statistical analysis was performed using the SAS 9.1 soft-
ware package. In the univariate analysis, independent
sample t-test and chi-square test were performed to
identify socio-demographic factors associated with full
remission, persistent depression, and episode, as well
as variables shared between them. Repeated-measures
ANOVA was used to estimate the time trends of vari-
ables shared between full remission and episode. Finally,
multiple-logistic regression was used to investigate the in-
dependent variables related to full remission, persistent
depression, and episode. The odds ratio and a 95% confi-
dence interval were used for categorical and continuous
variables. A p-value of <0.05 was considered statistically
significant.
Results
There were 151 participants that completed the baseline-
assessment interview, 111 of those 151 participants com-
pleted the second interview and assessment after 4 weeks,
and 78 participants completed the final interview and as-
sessment after 8 weeks. Of the remaining 78 patients, a
total of 21 (26.9%) were in full remission, 35 (44.9%) were
in persistent depressive symptom, and 22 (28.2%) were in
episode (Figure 1).
As shown in Table 2, demographic characteristics,
number of episodes, pharmacotherapy, and psychother-
apy were similar among patients in full remission, per-
sistent depression, and episode. Patients in full remission
were older (p = 0.03; p = 0.01), exhibited greater psycho-
social functioning, (p < 0.001), held more-positive beliefs
regarding antidepressant medication (p = 0.03; p = 0.02),
had higher self-efficacy (p = 0.001), and scored lower for
neuroticism (p = 0.003), as compared to patients in per-
sistent depression, and episode (Table 2).
In addition, repeated-measures ANOVA revealed that
in comparison with patients in episode, those in full remis-
sion showed significantly greater psychosocial functioning
Table 2 Comparison of predictors between full remission, persistent depression, and episode
Full remission (n = 21) Persistent depression (n = 57) Episode (n = 22) Pa Pb
Categorical variables* n % n % n %
Gender Male 11 52.4 18 31.6 8 36.4 0.29 0.09
Female 10 47.6 39 68.4 14 63.6
Education Junior high school
or below
10 47.6 28 49.1 13 59.1 0.65 0.97
Senior high school 6 28.6 17 29.8 6 27.3
College or above 5 23.8 12 21.0 3 13.6
Fixed family income No 4 19.0 17 29.8 7 31.8 0.27 0.34
Yes 17 81.0 40 70.2 15 68.2
Employment Unemployed 15 71.4 31 54.4 15 68.2 0.54 0.33
Employed 6 28.6 26 45.6 7 31.8
Religion None 6 28.6 17 29.8 5 22.7 0.51 0.73
Buddhism or Taoism 11 52.4 34 59.7 15 68.2
Others 4 19.0 6 10.5 2 9.1
Marital Status Single 2 9.5 7 12.3 3 13.6 0.31 0.16
Married 16 76.2 38 66.7 12 54.5
Other 3 14.3 12 21.0 7 31.8
Number of previous episodes <4 5 23.8 9 15.8 1 4.5 0.07 0.41
≧4 16 76.2 48 84.2 21 95.5
Pharmaco-therapy No 3 14.3 19 33.3 4 18.2 0.66 0.08
Yes 18 85.7 38 66.7 18 81.8
Psychotherapy No 14 66.7 47 82.5 16 77.3 0.54 0.21
Yes 7 33.3 10 17.5 6 22.7
Hospitalization 0 12 57.1 30 52.6 12 54.4 0.50 0.80
(times) 1 6 28.6 15 26.3 4 18.2
≧2 3 14.3 12 21.1 6 27.3
Continuous variables†
Age (years) 57.1 ± 14.0 48.3 ± 13.8 47.7 ± 13.2 0.03 0.01
Psychosocial functioning 5.9 ± 4.0 15.6 ± 9.4 18.3 ± 9.2 <0.001 <0.001
Beliefs regarding antidepressant medication 44.5 ± 4.7 42.0 ± 4.0 41.3 ± 4.7 0.03 0.02
Self-efficacy 45.6 ± 9.7 36.6 ± 10.7 32.4 ± 10.5 <0.001 0.001
Neuroticism 19.5 ± 5.5 24.1 ± 5.9 25.5 ± 6.9 0.003 0.003
*Categorical variables were compared with χ2 tests.
†Continuous variables were compared with independent sample t tests.
ap value for χ2 tests or t-tests, full remission v.s. episode.
bp value for χ2 tests or t-tests, full remission v.s. persistent depression.
Yeh et al. BMC Psychiatry 2014, 14:273 Page 5 of 9
http://www.biomedcentral.com/1471-244X/14/273(p < 0.001), more positive beliefs regarding antidepressant
medication (p < 0.001), greater self-efficacy for managing
and preventing depression (p < 0.001), and lower levels of
neuroticism (p < 0.001) at baseline assessment, after
4 weeks, and after 8 weeks. These are shown in Figures 2,
3, 4 and 5.
The multiple logistic regression models in univariate
analyses were used to examine which factors had inde-
pendent effects on patients in full remission as com-
pared with those in persistent depression, and patientsin full remission as compared with those in episode. As
shown in Table 3, psychosocial-functioning impairment
(OR = 1.11, 95% CI: 1.00-1.22) was the only significant
factor for patients in persistent depression. Episode was
significantly associated with psychosocial- functioning
impairment (OR = 1.12, 95% CI: 1.00-1.26) and poorer
self-efficacy (OR = 0.91, 95% CI: 0.82-1.00). After adjust-
ment for confounding factors, age, beliefs regarding anti-
depressant medication, and neuroticism were not












interview after 4 weeks
Completed final 
interview after 8 weeks
p-value for repeated ANOVA<0.001
Figure 2 The time-trend of psychosocial functioning among full-remission and episode subjects.
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Several important findings have emerged from this
study. An aspect of this study was evaluation of patients
in full remission compared to patients in persistent de-
pression and with those in episode. There are few stud-
ies that have evaluated the psychosocial and functional
outcomes of depression [3]. Our main finding with mul-
tiple logistic regressions was that psychosocial function-
ing was the main associated factor of full remission
compared with both persistent depression and episode.
This result was similar to Enns’ study [14], and it was










interview after 4 week
p-value for repeated ANO
Figure 3 The time-trend of drug beliefs among full-remission and epifunctional outcome with depression patients [19]. Func-
tional status is an important indicator in depression,
when depressed patients achieve full remission, they be
able to restore the premorbid psychosocial function sta-
tus, and to participant social activities regularly, and
confident for managing the depression [8,20,21].
Self-efficacy was another associated factor for patients in
full remission of depression compared to patients in epi-
sode. Self-efficacy could positively predict improvements
in depression-symptom scores over time within individ-
uals [10,11]. In this study, self-efficacy is also a significant


















interview after 4 weeks
Completed final 
interview after 8 weeks
p-value for repeated ANOVA<0.001
Figure 4 The time-trend of self-efficacy among full-remission and episode subjects.
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help MDD patients foster abilities to overcome or control
their depression symptoms, screen for warning signs of
deepening depression, and improve patients’ confidence
for managing their own life and disease. Collaborative
care management has been demonstrated to be effective
for improving depression outcomes [20].
Previous studies showed that younger patients were
more prevalent in persistent depression and episode. In
the present study, the mean age of the patients at high
risk for persistent depression and episode is around 47 to











interview after 4 wee
p-value for repeated ANOVA
Figure 5 The time-trend of neuroticism among full-remission and epifound that patients around 42 years old had poorer out-
comes of major depression as compared with 39.6 years.
They indicated that patients who encounter achievement
life events (for example, work or financial problems) and
interpersonal stressful life events (for example, relation-
ship discord or death of an important person), particu-
larly when they have an avoidant coping style, are at risk
for continued depressive symptoms [14]. In this study,
however, patients’ age, beliefs regarding antidepressant
medication, and neuroticism were significantly associated
with persistent depression and episode when compared




interview after 8 weeks
<0.001
sode subjects.
Table 3 The multiple logistic regression on the factors associated with persistent depression and episode compared
with full remission
Variable Full remission (n = 21) vs. persistent depression (n = 57) Full remission (n = 21) vs. episode (n = 22)
β value SE OR 95% CI p-value β value SE OR 95% CI p-value
Age −0.004 0.03 1.00 0.94-1.05 0.88 −0.02 0.04 0.98 0.91-1.06 0.67
Psychosocial functioning 0.10 0.05 1.11 1.00-1.22 0.04 0.12 0.06 1.12 1.00-1.26 0.04
Beliefs regarding antidepressant
medication
−0.02 0.07 0.98 0.85-1.13 0.78 −0.02 0.09 0.98 0.82-1.17 0.84
Self-efficacy −0.05 0.04 0.95 0.88-1.02 0.13 −0.10 0.05 0.91 0.82-1.00 0.04
Neuroticism −0.03 0.08 0.98 0.84-1.13 0.74 −0.07 0.10 0.93 0.76-1.14 0.49
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the causal relationship between age, psychosocial func-
tioning, beliefs regarding antidepressant medication, self-
efficacy, and neuroticism.
Resolutions of major depression should focus on both
symptoms and functional impairments. Depression leads
to high levels of unemployment, disabilities, and de-
creased work performance, and has serious effects on
patients, their families, and ultimately the community.
Thus, it is important to help patients manage their dis-
ease to avoid relapses, improve their quality of life, and
decrease associated disabilities [7].
The four factors that this study revealed to significantly
improve depression were psychosocial functioning, be-
liefs regarding antidepressant medication, self-efficacy,
and neuroticism. High neuroticism scores have been
found to be among the best predictors of persistent
depression [18], and neuroticism might be related to
stressful life events [16]. Therefore, relapse-prevention
programs should include: 1) Rebuilding psychosocial life
and functioning, 2) Encouragement of positive beliefs re-
garding antidepressant medication, 3) Reconstruction of
patients’ confidence in managing their depression and
preventing relapses, and 4) Management of life events.Limitations
Our study has several limitations. This small longitu-
dinal study (n = 151) only assessed clinical characteristics
with regard to their predictive values in short-term treat-
ment (2 months) with a limited numbers of visits (in our
case, 3 visits), and only 51.7% of the participants com-
pleted all three interviews. Any biases associated with
data-collecting, and the long-term predictive value of
the factors revealed to be significant in this study (psy-
chosocial functioning, beliefs regarding antidepressant
medication, self-efficacy, and neuroticism) are yet un-
known. Lacking patients’ history of antidepressant in-
take, we were unable to report on the efficacy and
quality of pharmacotherapy treatment (e.g., each partici-
pant’s antidepressant therapy dosage and duration prior
to our study) or to determine patient- and clinician-related factors that may have influenced whether antide-
pressants were continued.
We could not ascertain the types of treatment offered
beyond pharmacological interventions during the study
and the number of psychotherapy or combined-therapy
visits, if any, prior to our study. Aside from self-report
assessment of the duration of the current depressive epi-
sode, we could not ascertain to what extent interper-
sonal events and responses to depression (that is, coping
styles) played in the participants of our study. In the ab-
sence of complete patient case records, we were unable
to ascertain whether participants experienced more fre-
quent switches into or out of major depression, and
whether transient fluctuations influenced depression sta-
tus in-between each follow-up interval.
Clinical implications
Our findings have several clinical implications: (1) In
light of prior longitudinal studies, some of the predictors
highlighted in our short-term study of remission ap-
peared to have potentially long-term predictive values
[13,16]. More specifically, while low neuroticism scores
were found in our remitted patients, Katon et al. [18]
observed that severity of depression and high neuroti-
cism scores were the best predictors of persistent de-
pression. (2) As this is the first investigation of clinical
characteristics of remission in a Taiwanese population, it
may be enlightening to take into consideration that
pharmacological interventions seemed more habitually/
conventionally acceptable to Taiwanese outpatients than
other forms of professional interventions, such as psy-
chotherapy and/or combined therapy. (3) It would be
clinically meaningful to conduct a study on treatment
preferences or treatment availability for Taiwanese out-
patients with MDD.
Conclusions
Experts in depression treatment have gained insights
into how disabling and costly MDD is and how import-
ant it is to treat depressed patients to full remission
[1,22,23]. Expanding on previous studies, our findings
identify a number of factors correlated to full remission
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ing, more-positive beliefs regarding antidepressant medi-
cation, heightened self-efficacy in managing/preventing
depression, and lowered neuroticism.
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